• Submit to Marine Drugs Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text HTML
• Full-Text PDF [400 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Zawadzki, M
• Janosch, C
• Szechinski, J
• [+] on Google Scholar
• Zawadzki, M
• Janosch, C
• Szechinski, J
• [+] on PubMed
• Zawadzki, M
• Janosch, C
• Szechinski, J

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Mar. Drugs 2013, 11(6), 1920-1935; doi:10.3390/md11061920

Article

Perna canaliculus Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil, a Randomized Trial, without Placebo Control

Marek Zawadzki, Claudia Janosch *  and Jacek Szechinski

Clinic of Rheumatology and Internal Medicine, Academic Clinical Hospital, Wroclaw 50-556, Poland

* Author to whom correspondence should be addressed.

Received: 20 March 2013; in revised form: 8 May 2013 / Accepted: 21 May 2013 / Published: 5 June 2013

(This article belongs to the Special Issue Marine Compounds and Inflammation)

Download PDF Full-Text [400 KB, uploaded 5 June 2013 14:12 CEST]

Abstract: Osteoarthritis (OA) typically generates pain, reduced mobility and reduced quality of life. Most conventional treatments for osteoarthritis, such as non-steroidal anti-inflammatory drugs (NSAIDs) and simple analgesics, have side effects. PCSO-524™, a non polar lipid extract from the New Zealand Green Lipped Mussel, is rich in omega-3 fatty acids and has been shown to reduce inflammation in both animal studies and patient trials. This OA trial examined pain relief changes in relation to quality of life and safety of use for OA patients who took PCSO-524™ compared with patients who took fish oil (containing an industry standard EPA-18% and DHA-12% blend). PCSO-524™ patients showed a statistically significant improvement compared with patients who took fish oil. There was an 89% decrease in their pain symptoms and 91% reported an improved quality of life. Patients treated with fish oil showed significantly less improvement and a greater level of physical discomfort during the study. These results suggest that PCSO-524™ might offer a potential alternative complementary therapy with no side effects for OA patients.

Keywords: Perna canaliculus; PCSO-524™; Lyprinol^®; greenlipped mussel; osteoarthritis; arthritis; fish oil; pain relief; joint pain

Article Statistics

Citations to this Article

Cite This Article